With a new Administration and Congress, changes in personnel at FDA and new safety data being published, is 2021 the year when CBD will come out from under the FDA shadows to be legally marketed in all 50state?
This panel seeks to get to the bottom of the IFR and what it means for the hemp CBD industry currently and in the future. We may also touch on the intersection of USDA and FDA authority to regulate hemp-derived CBD products.
Using the current regulatory landscape of CBD as a jumping-off point, this panel will explore this new market from a regulatory standpoint. We will discuss what these cannabinoids are and how they are likely to be used; whether they will encounter similar regulatory obstacles as CBD in coming to market; and whether we should continue to think of cannabinoids as a unified “block” for regulatory purposes,or if they will each have separate paths.